References
- Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54,3206-221.
- Mørk A, Montezinho LC, Hovelsø N, et al. Lu AA21004, a novel antidepressant, modulates neurotransmitter levels and theta oscillations, and exerts pro-cognitive effects in rats. Eur Neuropsychopharmacol 2011;21(Suppl 3):S407-8.
- Nutt DJ. Beyond psychoanaleptics – can we improve antidepressant drug nomenclature? J Psychopharmacol 2009;23:343-5.
- Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91.
- American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn, Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000
- Montgomery S, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
- ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice, 1996. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf [Last accessed 9 July 2012]
- World Medical Association (WMA), 2008. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/[Last accessed 9 July 2012]
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
- Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
- Guy W. Clinical Global Impressions (028-CGI). In: Guy W ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:216-22
- Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008;23:70-83.
- Wade A, Despiegel N, Reines EH. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 2006;18:83-9.
- Dunner DL, Wilson M, Fava M, et al. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety 2008;25(5):E1-8.
- Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012, published online April 9 2012, doi:10.1177/0269881112441866
- Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 2003;64(Suppl 2):3-7.
- Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72.